Indivior stock edges higher as options activity and analyst targets point to further upside
Published on 08/19/2026 at 13:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Indivior Plc (GB00BYZ0C031) stock is trading in the high-$30s, with recent market data showing a closing price of $39.43 for Indivior Pharmaceuticals, Inc. (ticker INDV) on Nasdaq as of August 18, 2026, 4:00 p.m. ET.
Per a detailed market overview dated August 19, 2026, this level reflects a 0.90% gain on the prior regular session close, while extended-hours indications point to a modest pullback to $39.15, underlining active trading around the $39 mark.
At this price, one consensus compilation of analyst views cites an average target of $45.17, implying 14.5% upside from the $39.43 close and suggesting that professional forecasts still build in room for gains if the company delivers on its growth plans.
Market data and recent options signals
Recent options flow data published on August 19, 2026 highlights Indivior Pharmaceuticals, Inc. among names with notable trading interest, listing the stock at $39.43 in several bullish and mixed-flow entries.
These entries show single-day options notional values ranging from $10,000 to $174,000 tied to Indivior, paired with statistical signals of positive skew on certain contracts, a pattern that indicates a subset of traders are positioning for continued strength or volatility in the share price.
Alongside this options activity, equity data compiled on the same day confirms that Indivior's Nasdaq listing has delivered a gain of 9.9% from a prior reference level to reach $39.43, underlining that the shares have already appreciated meaningfully ahead of any next fundamental catalyst.
Analyst targets and upside context
An analyst consensus summary dated August 19, 2026 shows Indivior carrying an average rating score of 2.86 on a scale where higher values correspond to more positive views.
This profile is based on a mix of recommendations, including six buy ratings and one hold rating, with no sell ratings flagged in the same overview, a distribution that points to generally constructive sentiment across the covering analyst group.
Within that framework, the $45.17 consensus price target stands against the current $39.43 share price, quantifying potential upside of 14.5% and providing a concrete benchmark for investors assessing risk and reward at prevailing levels.
A separate India-focused investing portal, updated as of August 18, 2026, 11:45 p.m. India Standard Time, reports Indivior's share price at $39.29, with a day high of $39.92 and a day low of $39.08, reinforcing that liquidity is concentrated in a relatively tight band just below $40.
The same portal references a target price of $49, which represents a larger potential gain of 24.7% versus $39.29, indicating that some models envision a higher fair value range than the $45.17 consensus from the broader analyst set.
Taken together, these figures sketch a picture in which the market has already priced in part of the growth story, yet forecast numbers continue to point to scope for additional appreciation, provided execution on the business plan remains intact.
Business focus: addiction treatment portfolio
Indivior focuses its business on treatments for opioid use disorder and related addiction conditions, with a portfolio that includes sublingual and injectable formulations designed to support long-term recovery.
The company has targeted both traditional healthcare systems and newer access models as it expands its reach, aiming to grow volumes in regions where opioid-related harms remain a significant public health challenge.
In parallel, Indivior pursues lifecycle management and label-expansion strategies across its core molecules, seeking to extend duration of therapy and improve patient adherence, which are critical drivers of recurring revenue in addiction treatment.
Indivior shares around $39 as of latest session
As of the close on August 18, 2026, Indivior shares on Nasdaq finished at $39.43, with extended trading data early on August 19, 2026 marking the stock at $39.15.
This places the shares fractionally below the consensus target of $45.17 but above the prior reference level from which the stock has advanced 9.9%, situating the current price range as a midpoint between realized gains and projected upside.
Fact box
Company: Indivior Plc
ISIN: GB00BYZ0C031
Ticker: INDV
Exchange: Nasdaq
Price (as of August 18, 2026, 4:00 p.m. ET): $39.43 USD
Sector / Industry: Pharmaceuticals / Biotechnology
